Table 1.
Analysis of the treatment ranking
| Treatments | Outcomes of efficacy | Outcome of safety | ||||||
|---|---|---|---|---|---|---|---|---|
| Rank OS | SUCRA | Rank PFS | SUCRA | Rank encephalic PFS | SUCRA | Rank AEs | SUCRA-AEs | |
| Alectinib | 1 | 88% | 2 | 78% | 4 | 59% | 5 | 55% |
| Lorlatinib | 2 | 67% | 1 | 96% | 1 | 98% | 7 | 12% |
| Brigatinib | 3 | 56% | 4 | 55% | 2 | 73% | 6 | 24% |
| Alectinib 300 | 4 | 55% | 3 | 77% | 5 | 56% | 1 | 99% |
| Ceritinib | 5 | 50% | 7 | 15% | 6 | 21% | 8 | 8% |
| Ensartinib | 6 | 43% | 5 | 51% | 3 | 68% | 4 | 57% |
| Crizotinib | 7 | 29% | 6 | 27% | 6 | 21% | 2 | 79% |
| Platinum-based chemotherapy | 8 | 10% | 8 | 0% | 8 | 2% | 3 | 64% |
| I 2 | - | 39.6% | - | 58.7% | - | 73.7% | - | - |
-: no data